Lewes, DE -- (SBWIRE) -- 12/02/2016 -- The latest Pharmaceutical and Healthcare disease pipeline guide Renal Cell Carcinoma – Pipeline Review, H2 2016, provides an overview of the Renal Cell Carcinoma (Oncology) pipeline landscape.

Renal cell carcinoma (RCC, formerly known as hypernephroma) is a kidney cancer that originates in the lining of the proximal convoluted tubule. Symptoms include hematuria, loin pain, abdominal mass, malaise, which is a general feeling of feeling unwell, weight loss and/or loss of appetite, anemia resulting from depression of erythropoietin and erythrocytosis. The predisposing factors are age and hereditary factors. The disease is controlled by chemotherapy and radiation therapy.

The latest pipeline guide Renal Cell Carcinoma – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Renal Cell Carcinoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Renal Cell Carcinoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Renal Cell Carcinoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 13, 46, 42, 3, 34, 4 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 5, 3 and 4 molecules, respectively.Renal Cell Carcinoma.

Renal Cell Carcinoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Renal Cell Carcinoma (Oncology).

- The pipeline guide reviews pipeline therapeutics for Renal Cell Carcinoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Renal Cell Carcinoma (Oncology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Renal Cell Carcinoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Renal Cell Carcinoma (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Renal Cell Carcinoma (Oncology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Renal Cell Carcinoma (Oncology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Spanning over 793 pages "Renal Cell Carcinoma - Pipeline Review, H2 2016" report covers Introduction, Renal Cell Carcinoma Overview, Therapeutics Development, Drug Profiles, Appendix. This report overed Many Companies few are - AbbVie Inc, Acceleron Pharma, Inc., Advenchen Laboratories, LLC, Altor BioScience Corporation, Ambrx, Inc., Amgen Inc., Ampio Pharmaceuticals, Inc., Apac Biotech Pvt Ltd, arGEN-X BV, Argos Therapeutics, Inc., ARMO Biosciences, Inc., Arrowhead Pharmaceuticals, Inc., Astellas Pharma Inc., Bayer AG, Bio-Cancer Treatment International Limited, BIOCAD, Bionomics Limited.

For more information Visit at: http://www.marketresearchreports.com/global-markets-direct/renal-cell-carcinoma-pipeline-review-h2-2016

Related Reports;

Psoriatic Arthritis - Pipeline Review, H2 2016 - Visit at - http://www.marketresearchreports.com/global-markets-direct/psoriatic-arthritis-pipeline-review-h2-2016

Radiodermatitis - Pipeline Review, H2 2016 - Visit at - http://www.marketresearchreports.com/global-markets-direct/radiodermatitis-pipeline-review-h2-2016

About Market Research Reports, Inc.
Market Research Reports, Inc. is the world's leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

Yearly/Quarterly Report Subscription: http://www.marketresearchreports.com/subscriptions